Hemostemix Inc. (CVE:HEM – Get Free Report) passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of C$0.22 and traded as low as C$0.12. Hemostemix shares last traded at C$0.12, with a volume of 266,495 shares traded.
Hemostemix Price Performance
The stock has a market cap of C$16.76 million, a price-to-earnings ratio of -3.35 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a quick ratio of 0.48 and a current ratio of 0.04. The firm’s 50-day simple moving average is C$0.22 and its two-hundred day simple moving average is C$0.13.
Insider Activity
In other news, Director Peter Alan Lacey acquired 200,000 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was purchased at an average cost of C$0.15 per share, for a total transaction of C$30,000.00. 10.43% of the stock is owned by insiders.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Want to Profit on the Downtrend? Downtrends, Explained.
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Why Are These Companies Considered Blue Chips?
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
